Rémi DELANSORNE, CEO
Chief Executive Officer

Rémi DELANSORNE is 48 years old. He holds a veterinary doctorate from “Ecole Nationale Vétérinaire d’Alfort” and a PhD in life sciences from « Université Pierre et Marie Curie » (Paris VI). After a post-doctoral fellowship at the University of Texas Medical School in Houston, he joined the pharmaceutical industry in 1985 in Theramex, where he held several positions in pre-clinical R&D.until the company was integrated into the Merck Group (now Merck-Serono) in 2000. In 2002. Rémi Delansorne became Merck Global Head of Diabetes Research and responsible for the three preclinical sites in France. Then, he joined Hybrigenics in 2004 as Vice-President for R&D and was appointed CEO of the company in September 2005.

Jean-François DUFOUR-LAMARTINIE
Senior Director, Head of Clinical R&D

Jean-François Dufour-Lamartinie joined Hybrigenics in 2006 as Head of Clinical Research & Development. He has acquired a broad experience in the clinical development in oncology in his prior positions with pharmaceutical companies, clinical research organisations and as clinician at cancer research institutes such as the Institut Gustave Roussy. Before joining Hybrigenics, Jean-François Dufour-Lamartinie was Clinical Research Director of BioAlliance Pharma, a French biopharmaceutical company, for more than 3 years and contributed to the launch of their first drug on the market.

Guillaume BOISSY
Senior Director, Head of Bioinformatics & Information Systems

Guillaume Boissy, who holds a PhD in Molecular Biophysics, took part in the set-up of the first biological macromolecule X-ray crystallography unit at the INRA. At the same time, he taught computing and structural biology at the Paris 7 and Versailles Universities for five years. He gained experience in architecture of information systems and in modeling from the Master in Computing in the INSA of Lyon before joining Hybrigenics in 1999 as bioinformatics project manager. He was involved in industrialization efforts and in the design of two proprietary production platforms, and later was appointed as Head of Bioinformatics & Information Systems in 2005.